UroGen Pharma Ltd.
NASDAQ:URGN · NASDAQ Global Market
-$0.40 today
Vol 0.83M · Avg 0.79M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
145.5%
avg 14.4%
ROIC
-81.1%
avg -63.7%
ROA
-76.6%
avg -62.0%
Analysis
ROE is currently the strongest return metric at 145.5% versus its period average of 14.4%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Elizabeth A. Barrett | President, Chief Executive Officer & Director | $2.19M | — | 64 | $2,000.00 | <0.01% |
Jason Drew Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | $978,418.00 | — | 54 | $51,326.00 | 0.11% |
Mark Schoenberg | Chief Medical Officer | $730,240.00 | — | 68 | $139,763.00 | 0.29% |
Ron Bentsur | Advisor | $699,766.00 | — | 60 | $38,113.00 | 0.08% |
Christopher Degnan | Chief Financial Officer | $561,797.00 | — | 46 | $32,609.00 | 0.07% |
Alison Hardgrove | Senior Vice President of Human Resources | — | — | — | — | — |
David Lin | Chief Commercial Officer | — | — | — | — | — |
James Ottinger | Executive Vice President of Regulatory Affairs & Quality | — | — | — | $2,000.00 | <0.01% |
Michael J. Louie | Chief Development Officer | — | — | — | — | — |
Timothy Simon | Senior Vice President of Business Development & Portfolio Strategy | — | — | — | — | — |
Marina Konorty | Executive Vice President of Research & Development and Technical Operations | — | — | — | — | — |
Vincent I. Perrone | Senior Director of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
15
$1.49M
Net Sentiment
$1.49M
Net selling
Most Active
Schoenberg Mark
9 transactions
1–10 of 15
Analysis
Insiders reported 0 buys worth $0.00 and 15 sells worth $1.49M over the last 12 months. That adds up to net selling of $1.49M. Schoenberg Mark was the most active insider with 9 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +42.9% (13yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +42.9% (13yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.58B
AnaptysBio, Inc.
NASDAQ:ANAB
$2.39B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.89B
Mind Medicine (MindMed) Inc.
MNMD
$1.56B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.49B
Xencor, Inc.
NASDAQ:XNCR
$931.96M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$850.15M
Oculis Holding AG
NASDAQ:OCS
$637.44M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$610.42M
ProKidney Corp.
NASDAQ:PROK
$263.63M
Who manages URGN?
UroGen Pharma Ltd. (URGN) lists 12 active executives. The top listed executive is Mark Schoenberg, Chief Medical Officer.
Are URGN insiders buying or selling?
Recent insider activity shows net buying of $6.51M.
Explore More
Continue the stock analysis
Jump to another research area for this company.